



Frau Claudia Anders
Essen.Gesund.Vernetzt.- Medizinische Gesellschaft e.V.
c/o EWG Essener Wirtschaftsförderungsgesellschaft e.V.
Kennedyplatz 5
45127 Essen

Diabetes und Ernährungsmedizin

OÄ Dr. med. A. Mathew

Tel: 0201 – 723 – 6406 | Fax: 5655

diabetes@uk-essen.de

nutrition@uk-essen.de

Essen, den 27.05.2025

Bewerbung um den Jahrespreis 2025 - Kategorie „Gesundheit und Wissenschaft“

Sehr geehrte Frau Anders,

hiermit bewerbe ich mich um den Jahrespreis 2025 in der Kategorie „Gesundheit und Wissenschaft“.

Hierzu reiche ich unsere im April 2025 publizierte Arbeit mit dem Titel „*Impact of functionality and grading on survival in pancreatic neuroendocrine tumor patients receiving peptide receptor radionuclide therapy*“ ein, in der wir spezifische klinische Marker für das Therapieansprechen bei Patient:innen mit neuroendokrinen Tumoren identifiziert haben, um die Patient:innenauswahl und individualisierte Therapieplanung zu optimieren.

Für Rückfragen stehe ich jederzeit gerne zur Verfügung.

Mit freundlichen Grüßen

Annie Mathew

Grundinformationen

Kurzbeschreibung des Tätigkeitsbereichs:

Seit Februar 2017 bin ich an der Klinik für Endokrinologie, Diabetologie und Stoffwechsel des Universitätsklinikums Essen tätig, mit einem Schwerpunkt auf neuroendokrinen Tumoren (NET) und metabolischen Erkrankungen. Durch meine tägliche klinische Arbeit erkenne ich wiederkehrende diagnostische und therapeutische Herausforderungen, die ich gezielt in meiner Forschung aufgreife, um konkrete Lösungsansätze für die Versorgung unserer Patient:innen zu entwickeln.

Von 2022 bis 2025 wurde ich durch ein Forschungsstipendium des Universitätsklinikums Essen sowie der Deutschen Forschungsgemeinschaft (DFG) gefördert. Im Rahmen dieser Förderung habe ich mich neben der klinischen Versorgung, der patientennahen NET-Forschung gewidmet, mit dem Ziel, Diagnostik und Therapie durch die Identifikation prädiktiver Marker und die Entwicklung individualisierter Behandlungsstrategien zu verbessern.

Seit Oktober 2024 bin ich als Oberärztin tätig und leite den Schwerpunkt metabolische Erkrankungen und bin stellvertretend für den Bereich neuroendokrine Tumoren verantwortlich.

Ansprechpartnerin:

Dr. med. Annie Mathew

Klinik für Endokrinologie, Diabetologie und Stoffwechsel, Universitätsklinikum Essen
Hufelandstr. 55, 45147 Essen

E-Mail: annie.mathew@uk-essen.de

Tel.: 0201-723-82578

Allgemeinverständliche Zusammenfassung:

In dieser Studie untersuchten wir, welchen Einfluss Tumoreigenschaften wie die Hormonproduktion (Funktionalität), das Grading (biologische Aggressivität) und das Metastasierungsmuster auf das Überleben von Patient:innen mit fortgeschrittenen neuroendokrinen Tumoren (NET) der Bauchspeicheldrüse haben, die mit einer Peptidrezeptor-Radionuklidtherapie (PRRT) behandelt wurden. Diese Therapie ist bei metastasierten NET etabliert, jedoch gibt es bislang nur wenige Daten zur prädiktiven Bedeutung dieser klinischen Parameter.

Analysiert wurden 166 Patient:innen, die am Universitätsklinikum Essen behandelt wurden. Die Auswertung zeigte, dass ein niedriges Tumorgrading sowie eine höhere Anzahl an PRRT-Zyklen signifikant mit einem verlängerten Gesamtüberleben assoziiert waren. Das Vorliegen einer Knochenmetastasierung war mit einem signifikant schlechteren Überleben assoziiert. Die Hormonaktivität des Tumors hatte hingegen keinen relevanten Einfluss auf die Prognose.

Die Studie liefert praxisnahe und klinisch relevante Erkenntnisse, die eine differenzierte Auswahl geeigneter Patient:innen für die PRRT ermöglichen. Sie unterstreicht insbesondere die prognostische Bedeutung von Grading, Funktionalität und Knochenmetastasierung und leistet so einen wichtigen Beitrag zur personalisierten Diagnostik und Therapieplanung bei dieser seltenen und komplexen Tumorerkrankung.

Zusammenfassende Kurzbeschreibung

Innovationspotenzial:

Die Studie liefert erstmals eine evidenzbasierte Differenzierung von Patient:innen mit neuroendokrinen Tumoren der Bauchspeicheldrüse, die besonders von einer PRRT profitieren. Auf Basis einer strukturierten endokrinologischen Diagnostik identifiziert sie Risikokonstellationen, die bislang in Studien unterrepräsentiert waren, aber das Überleben entscheidend beeinflussen. Neue Erkenntnisse sind, dass funktionell aktive Tumoren häufiger auftreten als bisher angenommen und dass Knochenmetastasen prognostisch ähnlich ungünstig sind wie ein höheres Grading und für die Notwendigkeit einer frühzeitigen und intensiveren Therapie spricht. Die Arbeit schließt eine zentrale Versorgungslücke, stärkt die Rolle strukturierter Diagnostik und schafft eine fundierte Grundlage für personalisierte Therapieentscheidungen.

Nachhaltigkeit:

Die Studie trägt zur nachhaltigen Versorgung seltener Tumorentitäten bei, indem sie hilft, Ressourcen gezielt dort einzusetzen, wo sie wirksam sind. Durch die Identifikation von Patient:innen mit hoher PRRT-Ansprechrare können unnötige Therapien vermieden, Lebensqualität erhalten und Gesundheitssysteme entlastet werden.

Beitrag zur Lebensqualität:

Die präzisere Auswahl geeigneter Diagnostik und Therapieoptionen verlängert das Überleben von Patient:innen mit dieser seltenen Erkrankung und trägt dazu bei, belastende Nebenwirkungen und ineffektive Behandlungsversuche zu reduzieren.

Standortrelevanz:

Die Studie wurde vollständig am Universitätsklinikum Essen durchgeführt, einem Exzellenzzentrum für neuroendokrine Tumoren (ENETS Center of Excellence) und Referenzzentrum für seltene endokrine Erkrankungen (ENDO-ERN, EURACAN). Unsere klinische Infrastruktur verbindet endokrinologische Diagnostik mit nuklearmedizinischer Therapie wie PRRT und osteologischer Expertise. Diese interdisziplinäre Stärke macht Essen zu einem führenden Standort für die Versorgung und Forschung bei NET.

Anlagen:

- Lebenslauf
- Publikation

Curriculum Vitae

Dr. med. Annie Mathew

Anschrift Kahrstraße 85, 45128 Essen
Geburtsdatum und -ort 19.07.1989 in Bonn
Telefon 0201 723 82578
E-Mail annie.mathew@uk-essen.de



Beruflicher Werdegang

- seit 10/2024 Oberärztin, Klinik für Endokrinologie, Diabetologie und Stoffwechsel, Universitätsklinikum Essen
- 04/2023-09/2024 Fachärztin für Innere Medizin, Endokrinologie und Diabetologie, Klinik für Endokrinologie, Diabetologie und Stoffwechsel, Universitätsklinikum Essen
- 02/2017-03/2023 Assistenzärztin, Klinik für Endokrinologie, Diabetologie und Stoffwechsel, Universitätsklinikum Essen
- 12/2016 Approbation als Ärztin, Bezirksregierung Münster

Promotion

- 05/2021 The Role of the *RET* Proto-Oncogene in MEN2 Phenotype –Real-World Data from a Tertiary Referral Center, Universität Duisburg-Essen, Betreuerin: Prof. Dr. Dr. Führer-Sakel

Publikationen

- 04/2025 **Mathew A**, Kersting D, Fendler WP, Braegelmann J, Führer D, Lahner H. Impact of functionality and grading on survival in pancreatic neuroendocrine tumor patients receiving peptide receptor radionuclide therapy. *Front Endocrinol (Lausanne)*. 2025 Apr 15;16:1526470. doi: 10.3389/fendo.2025.1526470. PMID: 40303635; PMCID: PMC12037364.
- 10/2024 Welsner M, Navel H, Hosch R, Rathsmann P, Stehling F, **Mathew A**, Sutharsan S, Strassburg S, Westhölter D, Taube C, Zensen S, Schaarschmidt BM, Forsting M, Nensa F, Holtkamp M, Haubold J, Salhöfer L, Opitz M. Opportunistic Screening for Low Bone Mineral Density in Adults with Cystic Fibrosis Using Low-Dose Computed Tomography of the Chest with Artificial Intelligence. *J Clin Med*. 2024 Oct 7;13(19):5961. doi: 10.3390/jcm13195961. PMID: 39408020; PMCID: PMC11478210.
- 08/2024 Watanabe M, Leyser S, Theysohn J, Schaarschmidt B, Ludwig J, Fendler WP, Moraitis A, Lahner H, **Mathew A**, Herrmann K, Weber M. Dose-Response

- Relationship in Patients with Liver Metastases from Neuroendocrine Neoplasms Undergoing Radioembolization with ⁹⁰Y Glass Microspheres. J Nucl Med. 2024 Aug 1;65(8):1175-1180. doi: 10.2967/jnumed.124.267774. PMID: 38906556.
- 04/2024 Braegelmann J, **Mathew A**, Führer-Sakel D, Lahner H. Consanguineous couple with SDHD gene mutations: Diagnosis, treatment, and implications of family genetic testing. Clin Case Rep. 2024 Apr 4;12(4):e8572. doi: 10.1002/ccr3.8572. PMID: 38585582; PMCID: PMC10995254.
- 12/2023 **Mathew A**, Bertram S, Rawitzer J, Nottrott M, Farzaliyev F, Unger N, Weber F, Dralle H, Führer D, Lahner H. Hormonal Hypersecretion and Pain - Rare But Not To Be Forgotten. Am J Med. 2024 Apr;137(4):311-314. doi: 10.1016/j.amjmed.2023.11.025. Epub 2023 Dec 16. PMID: 38104643.
- 08/2023 **Mathew A**, Fendler WP, Theysohn J, Herrmann K, Führer D, Lahner H. Bone Metastases in Patients with Pancreatic NETs: Prevalence and Prognosis. Horm Metab Res. 2023 Dec;55(12):827-834. doi: 10.1055/a-2159-5548. Epub 2023 Aug 23. PMID: 37611636.
- 08/2022 Kroll L, **Mathew A**, Baldini G, Baldini G, Hosch R, Koitka S, Kleesiek J, Rischpler C, Haubold J, Fuhrer D, Nensa F, Lahner H. CT-derived body composition analysis could possibly replace DXA and BIA to monitor NET patients. Sci Rep. 2022;12(1):13419. Published 2022 Aug 4.
- 03/2022 **Mathew A**, Führer D, Lahner H. Artificial Sepsis: Think Twice Before Pausing Therapy. Am J Med. 2022 Mar;135(3):e73 4. doi: 10.1016/j.amjmed.2021.10.006. Epub 2021 Oct 28. PMID: 34717899.
- 12/2021 **Mathew A**, Führer D, Lahner H. Sunitinib-Induced Hypothyroidism and Survival in Pancreatic Neuroendocrine Tumors. Horm Metab Res. 2021 Dec;53(12):794-800. doi: 10.1055/a-1658-3077. Epub 2021 Dec 10. PMID: 34891209.
- 09/2021 Lahner H, **Mathew A**, Klocker AL, Unger N, Theysohn J, Rekowski J, Jöckel KH, Theurer S, Schmid KW, Herrmann K, Führer D. Streptozocin/5-fluorouracil chemotherapy of pancreatic neuroendocrine tumours in the era of targeted therapy. Endocrine. 2022 Jan;75(1):293-302. doi: 10.1007/s12020-021-02859-y. Epub 2021 Sep 4. PMID: 34480724; PMCID: PMC8763729.
- 07/2020 **Mathew A**, Latteyer S, Frank-Raue K, Moeller LC, Zwanziger D, Mengel M, Führer D, Tiedje V. A Novel Double RET E768D/L790F Mutation Associated with a MEN2B-Like Phenotype. Thyroid. 2021 Feb;31(2):327-329. doi: 10.1089/thy.2019.0472. Epub 2020 Jul 14. PMID: 32546069.

Preise/ Förderung

- 05/2025 Posterpreis „A Novel Model for Malignancy Prediction in Insulinoma - Development and Cross-Cohort Validation“ auf dem 131. Kongress der Deutschen Gesellschaft für Innere Medizin (DGIM)

03/2022-02/2025	Clinician Scientist im Rahmen des UMEA Clinician Scientist Programms der Medizinischen Fakultät der Universität Duisburg-Essen und der Deutschen Forschungsgemeinschaft (DFG)
05/2024	Posterpreis „NET ² - Improved diagnostics and therapy monitoring in patients with neuroendocrine tumors using an automated liver lesion segmentation network“ auf dem 130. Kongress der Deutschen Gesellschaft für Innere Medizin (DGIM)
03/2022	Posterpreis „Bone Metastases in Patients with pancreatic neuroendocrine tumors: Prevalence and clinical relevance“ auf dem 65. Kongress für Endokrinologie der Deutschen Gesellschaft für Endokrinologie (DGE)
03/2018	Posterpreis „New Double RET Mutation with MEN2B Phenotype“ auf dem 61. Kongress für Endokrinologie der Deutschen Gesellschaft für Endokrinologie (DGE)

Zusätzliche Qualifikationen

01/2025	Diabetologin DDG (Deutsche Diabetes Gesellschaft)
09/2024	Osteologin DVO (Dachverband Osteologie)
2018-2024	Good Clinical Practice (GCP) Grundkurs, Auffrischkurs für Prüfer und Stellvertreter, Aufbaukurs für Prüfer und Hauptprüfer
10/2020	Weiterbildung gemäß §4, Abs. 8 in Ernährungsmedizin durch die Deutsche Gesellschaft für Ernährung (DGE)

Mitgliedschaften

Deutsche Gesellschaft für Endokrinologie (DGE)
European Neuroendocrine Tumor Society (ENETS)
Deutsche Diabetes Gesellschaft (DDG)
Deutsche Gesellschaft für Innere Medizin (DGIM)
Deutsche Gesellschaft für Lipidologie (DGFL)

Essen, 27.05.2025

Annie Matthes



OPEN ACCESS

EDITED BY

Pernille Holmager,
University of Copenhagen, Denmark

REVIEWED BY

Shuai Ren,
Affiliated Hospital of Nanjing University of
Chinese Medicine, China
Dan Granberg,
Karolinska Institutet (KI), Sweden

*CORRESPONDENCE

Harald Lahner
✉ harald.lahner@uk-essen.de

RECEIVED 11 November 2024

ACCEPTED 19 March 2025

PUBLISHED 15 April 2025

CITATION

Mathew A, Kersting D, Fendler WP,
Braegelman J, Fuhrer D and Lahner H (2025)
Impact of functionality and grading on
survival in pancreatic neuroendocrine tumor
patients receiving peptide receptor
radionuclide therapy.
Front. Endocrinol. 16:1526470.
doi: 10.3389/fendo.2025.1526470

COPYRIGHT

© 2025 Mathew, Kersting, Fendler,
Braegelman, Fuhrer and Lahner. This is an
open-access article distributed under the terms
of the [Creative Commons Attribution License](#)
(CC BY). The use, distribution or reproduction
in other forums is permitted, provided the
original author(s) and the copyright owner(s)
are credited and that the original publication
in this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Impact of functionality and grading on survival in pancreatic neuroendocrine tumor patients receiving peptide receptor radionuclide therapy

Annie Mathew¹, David Kersting², Wolfgang P. Fendler²,
Johanna Braegelman¹, Dagmar Fuhrer¹ and Harald Lahner^{1*}

¹Department of Endocrinology, Diabetes and Metabolism and Division of Laboratory Research, University Hospital Essen, University Duisburg-Essen, Essen, Germany, ²Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

Background: Peptide receptor radionuclide therapy (PRRT) is a well-established treatment option for neuroendocrine tumors (NET), yet randomized controlled trials have not provided data on its impact on overall survival. The real-world efficacy of PRRT and its association with tumor functionality and grading in pancreatic neuroendocrine tumors (PanNET) remains underexplored.

Methods: A retrospective analysis of 166 patients with histologically confirmed metastatic PanNET was performed. Subgroup analyses examined progression-free survival (PFS) and overall survival (OS) following PRRT cycles, stratified by tumor grading, tumor functionality and bone metastases.

Results: Of 166 patients, 100 (60.2%) received PRRT with a median of four cycles. In the PRRT cohort, 68% of patients had deceased. PFS after four and eight consecutive cycles was 20 and 18 months, respectively ($p=0.4$). OS for the entire cohort was 79 months, with patients receiving 4+ cycles of PRRT having an OS of 87 months and those receiving 5+ cycles achieving an OS of 100 months. Patients with grade 1 or 2 tumors had a significantly longer median OS of 97 months compared to 74.5 months for grade 3 tumors ($p = 0.0055$). There was no significant difference in OS between functioning and non-functioning tumors after PRRT. Patients with bone metastases who received PRRT had a significantly shorter OS than those without (74 vs. 89 months, $p = 0.013$). In 19% of patients who received PRRT, therapy was discontinued due to progressive disease, toxicity or death.

Conclusions: Patients receiving extended cycles of PRRT showed improved survival outcomes in metastatic PanNET, particularly in patients with lower tumor grades and without bone metastases. No survival difference was seen between functioning and non-functioning PanNET, while patients with grade 3 tumors and bone metastases had significantly shorter survival despite PRRT.

KEYWORDS

pancreas, survival, PRRT, neuroendocrine tumor, PanNET, functionality

Introduction

Peptide receptor radionuclide therapy (PRRT) is an effective treatment for advanced neuroendocrine tumors (NET) of the gastrointestinal (GI) tract, but there is limited evidence regarding its efficacy in patients with pancreatic NET (PanNET) (1–3).

Current European Neuroendocrine Tumor Society (ENETS) guidelines recommend PRRT for patients with metastatic grade 1 or 2 PanNET with positive somatostatin receptor imaging (SRI), particularly in symptomatic or slowly progressive cases after use of somatostatin analog (SSA) therapy (4). For patients with symptomatic or rapidly progressing PanNET, alkylating chemotherapy should be considered prior to the use of PRRT, everolimus or sunitinib (5).

The recently published NETTER-2 trial evaluated the efficacy of PRRT in combination with octreotide LAR as first-line therapy for a sub-group of grade 2 (proliferation marker Ki-67 $\geq 10\%$) and grade 3 gastroenteropancreatic (GEP) NET. It demonstrated significant improvements in median progression-free survival (PFS), positioning it as a potential new standard of care in the first-line setting (2). However, since long-term follow-up is missing, the trial did not report on overall survival outcomes.

While the efficacy of PRRT was demonstrated in randomized controlled trials, real-world studies are essential to understand how these findings translate to broader, unselected patient populations (6, 7). This includes individuals with different tumor grades and functioning versus non-functioning tumors, which are often not fully represented in controlled trials (1, 2). This study addresses this gap by investigating the effects of PRRT on PanNET patients, focusing on the impact of tumor grading, functionality and other prognostic factors on survival outcomes. In addition, we focus on the real-world incidence of treatment discontinuation and its causes in a single center.

Materials and methods

Patients were identified from our prospective NET database at the European Neuroendocrine Tumor Society (ENETS) Center of Excellence, Department of Endocrinology, Diabetes and Metabolism, University Hospital Essen, Germany. Eligible patients were those with histologically confirmed, differentiated, metastatic PanNET treated at our center between September 2010 and August 2024 with all records in our endocrine tumor center. All patients were reviewed by a multidisciplinary tumor board before initiation and at completion of treatment. Tumor response was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

Data is reported as the number of patients (percentage of group) for categories and as median (lower-upper quartiles) for quantitative variables, unless otherwise noted. Progression-free survival (PFS) was calculated from the first day of the first PRRT cycle to documented progression or death. Overall survival (OS) was measured from initial

NET diagnosis to death from any cause. OS and PFS were analyzed using the Kaplan-Meier method and compared using the log-rank test. Bonferroni correction and False Discovery Rate (FDR) adjustment were applied to control for multiple comparisons and reduce the risk of Type I errors. To account for potential confounding factors, a multivariate Cox proportional hazards regression analysis was conducted to evaluate the independent effects of treatment cycles on OS and PFS. Tests were two-tailed and results at $p < 0.05$ were considered statistically significant. All statistical analyses were performed using R 4.4.2 (Posit Software, PBC, Boston, MA, USA). Written informed patient consent and approval for data collection and analysis were obtained upon admission to our institution. The study was approved by the Ethics Committee of the Medical Faculty of the University of Duisburg-Essen (18-8367-BO).

Results

Patient characteristics

We identified 166 consecutive metastatic PanNET patients, 82 females and 84 males (Table 1). The median age of the cohort at initial diagnosis was 56 years. The median Ki-67 index was 7%, with the Ki-67 data available for 161 patients (97%). Tumor grading revealed that 35 patients were classified as G1, 105 as G2 and 21 as G3 based on the World Health Organization criteria (8). Among the cohort, 19 patients (11.4%) had functioning tumors, including nine insulinomas (5.4%), eight gastrinomas (4.8%), and two VIPomas (1.2%), while the remaining 147 patients (88.6%) had non-functioning tumors. At the time of analysis, 100 patients (60.2%) were deceased.

PRRT subgroup analysis

Within the cohort, 100 patients (60.2%) received PRRT. There were 41 females and 59 males in this subgroup. The median age at initial diagnosis remained consistent at 56 years. Tumor grading in the PRRT group showed 21 patients with G1, 68 with G2 and nine with G3 tumors and a median Ki-67 index of 8%. Tumor functionality in the PRRT group showed that 88 were non-functioning (88%) and 12 were functioning (12%) with seven insulinomas (7%), four gastrinomas (4%) and one VIPoma (1%). Patient status in this subgroup showed that 37 patients (37%) were alive and 63 were deceased (63%). The median number of cycles of PRRT administered was four. In patients who received less than four cycles of PRRT ($n=17$), the reason for PRRT discontinuation was progressive disease ($n=8$), hematotoxicity ($n=2$), increase in liver enzymes ($n=1$), inadequate SSTTR uptake ($n=1$), duodenal perforation ($n=1$) and death ($n=4$). In two additional patients, PRRT was discontinued due to progressive disease after cycle five ($n=1$) and renal failure after cycle nine ($n=1$). In total, PRRT was discontinued in 19 patients (19%) due to adverse events.

TABLE 1 Patient characteristics of the whole PanNET cohort (n=166) and the PRRT PanNET cohort (n=100).

Characteristic	Whole Cohort	PRRT Cohort
Total Number of Patients	166 (100%)	100 (100%)
Sex		
- Female	82 (49.4%)	41 (41%)
- Male	84 (50.6%)	59 (59%)
Patient Status		
- Alive	66 (39.8%)	37 (37%)
- Dead	100 (60.2%)	63 (63%)
Median Age at Initial Diagnosis, years	56	56
Grading		
- G1	35 (21.1%)	21 (21%)
- G2	105 (63.3%)	68 (68%)
- G3	21 (12.7%)	9 (9%)
- Unknown	5 (2.9%)	2 (2%)
Ki-67 Index		
- 0-5%	76 (45.8%)	44 (44%)
- 6-10%	42 (25.3%)	27 (27%)
- 11-20%	22 (13.3%)	18 (18%)
- >20%	21 (12.7%)	9 (9%)
- Unknown	5 (2.9%)	2 (2%)
Median Ki-67 Index, %	7	8
NET Functionality		
- Non-Functioning	147 (88.6%)	88 (88%)
- Functioning	19 (11.4%)	12 (12%)
Median Observation Time, months	77	81
Median Overall Survival, months	79	83
Patients with Bone Metastases	60 (36.1%)	43 (43%)
Median Cycles of PRRT	–	4
Number of PRRT Cycles	–	
- <4 cycles	–	32 (32%)
- 4 cycles	–	45 (45%)
- 5-8 cycles	–	19 (19%)
- >8 cycles	–	4 (4%)

Bold values indicate headings.

Progression-free survival and response rate

PFS was analyzed in patients who received four and eight continuous cycles of PRRT. Fifty patients had progressed after four cycles of PRRT, with a median PFS of 20 months (95% CI 15-25

months). The best responses after four cycles were partial response (PR) in 19 patients (38%) and stable disease in 17 patients (34%). Treatment failure was observed in 14 patients, with progressive disease (PD) in 12 patients (24%) and mixed response in two patients (4%), leading to a change in treatment. The disease control rate (DCR) was 72% and the objective response rate (ORR) was 38%. Twelve patients who completed eight cycles of PRRT were evaluated with a median PFS of 18 months (95% CI 10-26 months). The difference in PFS was not statistically significant (p = 0.4). The best responses included PR in three patients (25%), stable disease in six patients (50%) and PD in three patients (25%). The DCR was 75% and the ORR was 25%.

Overall survival

The overall median OS for the entire cohort of 166 patients was 79 months (95% CI 7-251), with a median Ki-67 index of 7% (Figure 1). Patients who did not receive PRRT had a lower median OS of 67 months (95% CI 4-234), with a median Ki-67 index of 5% (Table 2). The subgroup of patients who received exactly two cycles of PRRT had the lowest median OS at 59 months (95% CI 21-210). This group had a higher median Ki-67 index of 10% and a significant number of patients with bone metastases (60%). Patients who received four cycles of PRRT had a median OS of 79 months (95% CI 19-223), the same as the overall cohort (Figure 2). This subgroup had a lower median Ki-67 index of 5%, a median age at diagnosis of 56 years and 42% of patients with bone metastases. There was a slight male predominance compared to those who did not receive PRRT. Patients who received four cycles and more of PRRT (“4+ cycles”) showed a median OS of 87 months (95% CI 22-220) and a median Ki-67 index of 10%. The median age at diagnosis was 56 years, 37% had bone metastases and 60% were male. Patients who received 5+ cycles PRRT showed the longest median OS of 100 months (95% CI 52-194) despite a higher median Ki-67 index of 10%. The proportion of patients with bone metastases was lower at 26%, comparable to the “no PRRT” group. The median age at diagnosis was 55 years, the youngest of all subgroups, with a male predominance of 65%.

Grading, functionality and bone metastases

We further analyzed the median OS in patients who received 4+ cycles of PRRT, i.e. the largest group with a longer median survival in correlation to different gradings. The median OS was 97 months (95% CI 84-101) in G1 and G2 PanNET patients and 74.5 months (95% CI 31-79) in G3 PanNET patients (Figure 3). The difference was statistically significant (p = 0.0055, Bonferroni-adjusted p = 0.022, FDR-adjusted p = 0.011). When comparing the non-functioning NET group to the functioning group, the median overall survival was 88.5 months (95% 79-100) vs 81 months (95% CI 61-87) (p = 0.82) when treated with 4+ cycles of PRRT.




FIGURE 1
Kaplan–Meier curve for median OS in months for the entire cohort, n=166.

Patients with bone metastases who received 4+ cycles of PRRT had a median OS of 74 months (95% CI 61–87) compared to 89 months (95% CI 84–101) in patients who did not have bone metastases (Figure 4). The difference was statistically significant ($p = 0.013$, FDR adjustment ($p = 0.017$), Bonferroni correction ($p = 0.052$)).

Multivariate analysis

We conducted a Cox proportional hazards regression analysis to evaluate the prognostic impact of various clinical parameters on OS and PFS after 4 cycles of PRRT. In the total cohort, the multivariate Cox regression analysis identified significant predictors of OS (Figure 5).

Higher tumor grading was a significant prognostic factor (HR: 2.75, 95% CI: 1.32–5.73, $p = 0.007$), with G3 tumors showing worse survival outcomes. The presence of bone metastases was significantly associated with poorer survival (HR: 1.74, 95% CI: 1.15–2.62, $p = 0.009$). PRRT treatment showed a significant association with improved OS, with HRs of 0.59 (95% CI: 0.35–0.99, $p = 0.044$) for 4 cycles and 0.50 (95% CI: 0.26–0.97, $p = 0.041$) for more than 4 cycles. Age at diagnosis showed a trend toward statistical significance, with an estimated hazard ratio (HR) of 1.50 (95% CI: 0.95–2.38, $p = 0.083$), indicating a possible increase in mortality risk with advancing age.

In the subgroup of patients who received PRRT (Figure 6), the Cox regression model showed that bone metastases remained a significant prognostic factor for worse survival (HR: 1.96, 95% CI: 1.17–3.28, $p = 0.01$). Tumor grading (HR: 2.50, 95% CI: 0.88–7.06, $p = 0.08$) and age (HR: 1.05, 95% CI: 0.55–2.01, $p = 0.87$) were not statistically significant in this subgroup. Gender and tumor functionality did not show significant associations with OS in the PRRT subgroup.

PFS after four continuous PRRT cycles was analyzed in 49 patients (Figure 7). The presence of bone metastases was the strongest predictor of shorter PFS, with an HR of 5.57 (95% CI: 1.73–17.87, $p = 0.004$). Tumor grading (HR: 4.03, 95% CI: 0.85–19.10, $p = 0.079$) did not reach statistical significance. Age at diagnosis, tumor functionality and gender were not significant predictors of PFS in this cohort.

Discussion

Our study analyzed the impact of grading and functionality on the effectiveness of PRRT in patients with metastatic PanNET. Approximately 60% of our PanNET cohort underwent PRRT, highlighting the frequent use of PRRT at our center. The high mortality rate in our cohort (60.2% deceased at the time of analysis)

TABLE 2 Median OS and patient characteristics for the whole cohort and subgroups.

Group, n	Median OS in months	Median Ki-67 in %	Median Age at initial diagnosis	Patients with bone metastases, n	Sex female/male
Whole cohort (n=166)	79	7	56	36% (60)	82/84
No PRRT (n= 66)	67	5	56	26% (17)	41/25
2 cycles PRRT (n=15)	59	10	52	60% (9)	8/7
4 cycles PRRT (n=45)	79	5	56	42% (19)	19/26
4+ cycles PRRT (n=68)	87	7	56	37% (25)	27/41
5+ cycles PRRT (n=23)	100	10	55	26% (6)	8/15

Bold values indicate headings.




FIGURE 2

Kaplan–Meier analysis for median OS in months for subgroups who received 2 cycles (red), 4 cycles (green) and 5+ cycles (blue) of PRRT, $p = 0.0024$.

underscores the aggressive nature of metastatic PanNET and the need for optimized treatment strategies (4, 9–11).

PRRT demonstrated favorable disease control in patients with advanced PanNET, achieving a DCR of 72% after four cycles and 75% after eight cycles. The ORR reflecting the proportion of patients who achieved PR was 38% after four cycles and decreased to 25% after eight cycles. This suggests that while PRRT continues to stabilize disease in most patients throughout treatment, the likelihood of achieving a significant tumor shrinkage diminishes as treatment progresses. The DCR remained high, indicating that PRRT effectively halts tumor progression in most patients, even with extended cycles.

Recently, the authors of the NETTER-2 data stated that PRRT should be considered a new standard of care as first-line therapy for grade 2 and 3 GEP-NET, extending median PFS to 22.8 months in the PRRT arm compared to 8.5 months in the high-dose octreotide 60 mg LAR (control) arm (2).

In contrast, our study analyzed a cohort of metastatic PanNET patients, including those who received different cycles of PRRT. Compared to NETTER-2, which focused on first-line therapy, our study includes any-line therapy. This distinction is critical as our results reflect outcomes across different phases of treatment rather

than a first-line intervention. NETTER-2's focus on G2/3 tumors contrasts with our inclusion of more than 20% of G1 PanNET, allowing for a more comprehensive evaluation of the real-world effectiveness of PRRT. This likely reflects the common practice of using PRRT not only in advanced, high-grade tumors but also in well-differentiated, lower-grade PanNET underscoring the potential role of PRRT beyond its traditional indication for more aggressive disease. The current developments might lead to an even more prominent role of PRRT in the treatment of low-grade PanNET in the future.

The OCLURANDOM trial is the first multicenter, randomized, open-label phase II study to evaluate the anti-tumor activity of Lu-177 DOTATATE (12). The two-arm randomized study of PRRT and sunitinib met its primary endpoint by achieving significant PFS with a median of 20.7 months in the PRRT arm and 11 months in the sunitinib arm. Median PFS in our PRRT cohort was similar with 20 and 18 months at four and eight cycles, respectively. Other trials evaluating the efficacy of PRRT are ongoing, such as COMPOSE (13).

Another important finding of our study is the association between the number of PRRT cycles and OS. Patients who received more than four cycles of PRRT showed the longest median OS of 100 months, despite a higher median Ki-67 index





FIGURE 3

Kaplan–Meier analysis for median OS in months for patients with G1/2 and G3 who received 4+ cycles of PRRT.



of 10%, which may be related to earlier and more aggressive interventions. Multivariate Cox regression analysis showed a significant association with improved OS in the PRRT cohort, with HRs of 0.59 (95% CI: 0.35–0.99, $p = 0.044$) for 4 cycles and 0.50 (95% CI: 0.26–0.97, $p = 0.041$) for more than four cycles.


Our results also highlight the significant heterogeneity in patient response to PRRT. For example, the cohort of patients who received exactly two cycles of PRRT had a significantly lower median OS of 59 months, suggesting a limited benefit from fewer cycles. The presence of bone metastases had a significant impact on OS in our study. Patients with bone metastases who received 4+ cycles of PRRT had a median OS of 74 months compared to 89 months for patients without bone metastases ($p = 0.013$). This finding highlights the challenge of treating bone metastases and suggests that additional or more aggressive therapeutic strategies may be needed for patients with such metastases (14). It was further supported by our multivariate analysis, where bone metastases remained a significant prognostic factor in the PRRT subgroup (HR: 1.96, $p = 0.01$).

In contrast, patients with lower-grade tumors (G1/G2) and lower Ki-67 indices who received 4+ cycles of PRRT had a significantly longer median OS of 87 months vs. 74.5 months in G3 PanNET.

Interestingly, no significant difference in OS was observed between patients with functioning versus non-functioning PanNET who received 4+ cycles of PRRT (median OS of 81 months vs. 88.5 months, $p = 0.82$). This suggests that the functional status of the tumor may not significantly influence the response to PRRT. This finding may support the broader use of PRRT across different PanNET subtypes, regardless of their hormonal activity.

Notably, PRRT was discontinued in 19% of patients due to progressive disease, toxicity or death, highlighting the importance of monitoring treatment tolerability. The longevity of toxic effects remains to be analyzed and long-term follow-up is required.

Selection bias, particularly due to survival bias, may have influenced our results. Patients who lived long enough to receive multiple cycles of PRRT likely had inherently better overall health,






FIGURE 6

Hazard Ratios (HR) and 95% Confidence Intervals (CI) for Overall Survival in PRRT cohort, n=98.

characterized by favorable prognostic factors such as robust blood counts, preserved renal function and SRI positivity. These factors do not only make patients eligible for PRRT, they are also independently associated with improved survival, which may partly explain the longer OS observed in those who received four or more cycles. The lack of a randomized control or prospective study design further complicates the interpretation of the survival benefit of PRRT, as patients with more favorable baseline characteristics may have been preferentially selected to continue therapy.

A major limitation of the study is that treatment sequencing was not analyzed. The heterogeneity of patient presentation, tumor biology and response to treatment made it difficult to establish comparable subgroups for analysis of treatment sequencing. As a result, we could not determine the optimal sequence or combination of treatments, such as PRRT, chemotherapy or

molecular targeted therapies, which limits the ability to provide clear guidance for clinical practice. The diversity of tumor grades, Ki-67 indices, and progression patterns make it difficult to draw generalized conclusions about the best treatment pathways for metastatic PanNET. Future prospective studies are needed to explore optimal sequencing strategies to improve treatment efficacy and patient outcomes.

A key area for future research is to determine which patients are most likely to benefit from re-PRRT and the optimal timing for re-treatment. Further studies should investigate whether patients with more aggressive tumors (higher Ki-67) could benefit from earlier initiation of PRRT and whether subsequent re-treatment at specific intervals could further prolong survival. The optimal interval between PRRT courses remains an open question and could be influenced by factors




FIGURE 7

Hazard Ratios (HR) and 95% Confidence Intervals (CI) for Progression-Free Survival after 4 PRRT Cycles, n=49.

such as tumor biology, previous treatment response and overall patient condition.

In conclusion, while our study confirms the benefit of PRRT in prolonging survival in metastatic PanNET patients, particularly with more cycles, it also highlights the need for comparative studies and further investigation into treatment sequencing and personalized patient management. Integrating findings from studies such as NETTER-2 with our results may provide a more nuanced understanding of the role of PRRT in treating advanced PanNET and improving patient outcomes.

Conclusion

PRRT demonstrated prolonged disease stabilization and a potential survival benefit in metastatic PanNET patients, especially when administered in extended cycles. G3 PanNET and bone metastases remain challenging, highlighting the need for tailored therapeutic strategies in this subset. These findings align with the results of randomized trials such as NETTER-2, while further highlighting the prolonged overall survival benefit, underscoring the role of PRRT as a valuable treatment option including functioning PanNET. Further research is needed to optimize the sequencing of therapy, understand the role and timing of re-PRRT and explore personalized approaches that integrate PRRT with other systemic treatments to improve patient outcomes.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving humans were approved by Medical faculty of the University Duisburg-Essen (18-8367-BO). The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required from the participants or the participants' legal guardians/next of kin in accordance with the national legislation and institutional requirements.

References

1. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors. *N Engl J Med*. (2017) 376:125–35. doi: 10.1056/NEJMoa1607427
2. Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, et al. all the, [(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. *Lancet*. (2024) 403:2807–17. doi: 10.1016/S0140-6736(24)00701-3
3. Del Rivero J, Perez K, Kennedy EB, Mittra ES, Vijayvergia N, Arshad J, et al. Systemic therapy for tumor control in metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO guideline. *J Clin Oncol*. (2023) 41:5049–67. doi: 10.1200/JCO.23.01529
4. Kos-Kudla B, Castano JP, Denecke T, Grande E, Kjaer A, Koumariannou A, et al. European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours. *J Neuroendocrinol*. (2023) 35: e13343. doi: 10.1111/jne.13343

Author contributions

AM: Conceptualization, Data curation, Formal Analysis, Methodology, Validation, Visualization, Writing – original draft, Writing – review & editing, Investigation, Software. DK: Writing – review & editing, Investigation, Methodology, Validation. WF: Writing – review & editing, Investigation. JB: Writing – review & editing. DF: Writing – review & editing, Conceptualization, Methodology, Supervision, Validation. HL: Conceptualization, Methodology, Validation, Writing – review & editing, Formal Analysis, Investigation, Supervision.

Funding

The author(s) declare that financial support was received for the research and/or publication of this article. We acknowledge support by the Open Access Publication Fund of the University of Duisburg-Essen.

Conflict of interest

DK reports a research grant from Pfizer and speaker honoraria from Pfizer and Novartis outside of the submitted work.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

5. Hofland J, Falconi M, Christ E, Castano JP, Faggiano A, Lamarca A, et al. European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes. *J Neuroendocrinol.* (2023) e13318. doi: 10.1111/jne.13318
6. Almeamar H, Cullen L, Murphy DJ, Crowley RK, Toumpanakis C, Welin S, et al. Real-world efficacy of lutetium peptide receptor radionuclide therapy in patients with neuroendocrine tumours. *J Neuroendocrinol.* (2022) 34:e13138. doi: 10.1111/jne.13138
7. Sukrihan V, Armbruster H, Rogers S, Vogt SM, Grenade C, Verschraegen C, et al. Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience. *PLoS One.* (2024) 19:e0298824. doi: 10.1371/journal.pone.0298824
8. Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. *Endocr Pathol.* (2022) 33:115–54. doi: 10.1007/s12022-022-09708-2
9. Ren S, Qian L, Daniels MJ, Duan S, Chen R, Wang Z. Evaluation of contrast-enhanced computed tomography for the differential diagnosis of hypovascular pancreatic neuroendocrine tumors from chronic mass-forming pancreatitis. *Eur J Radiol.* (2020) 133:109360. doi: 10.1016/j.ejrad.2020.109360
10. Ren S, Chen X, Wang Z, Zhao R, Wang J, Cui W, et al. Differentiation of hypovascular pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinoma using contrast-enhanced computed tomography. *PLoS One.* (2019) 14:e0211566. doi: 10.1371/journal.pone.0211566
11. Guo CG, Ren S, Chen X, Wang QD, Xiao WB, Zhang JF, et al. Pancreatic neuroendocrine tumor: prediction of the tumor grade using magnetic resonance imaging findings and texture analysis with 3-T magnetic resonance. *Cancer Manag Res.* (2019) 11:1933–44. doi: 10.2147/CMAR.S195376
12. Baudin E, Walter TA, Beron A, Smith D, Hadoux J, Lachachi C, et al. First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionuclide therapy with ¹⁷⁷Lutetium –DOTA-Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: results of the OCLURANDOM trial. *Ann Oncol.* (2022) 33:410. doi: 10.1016/j.annonc.2022.07.1013
13. Halfdanarson TR, Reidy-Lagunes DL, Vijayvergia N, Harris P. Pivotal phase III COMPOSE trial will compare ¹⁷⁷Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors. *J Clin Oncol* 40. (2022) 40(4_suppl):TPS514–TPS514. doi: 10.1200/JCO.2022.40.4_suppl.TPS514
14. Mathew A, Fendler WP, Theysohn J, Herrmann K, Fuhrer D, Lahner H. Bone metastases in patients with pancreatic NETs: prevalence and prognosis. *Horm Metab Res.* (2023) 55:827–34. doi: 10.1055/a-2159-5548